Drug Trial Radar · NCT06432166
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Dec 30, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- MTI Biotech IncIndustry
- Sponsor type
- Industry
- Collaborators
- Vanderbilt University Medical Center
- First posted
- May 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants. Participants will be randomized 1:1:1:1 to receive 250 mg BID, 250 and 500 mg 2-HOBA acetate TID or placebo for 12 weeks. Blood and cerebral spinal fluid (CSF) will be collected to measure markers of protein modification by dicarbonyls (IsoLGs- \& MDA), pTau-181, YKL-40, and NF-L.
Conditions
- Alzheimer Disease
- Mild Cognitive Impairment
Interventions
2-hydroxybenzylamine acetateDrug
2-hydroxybenzylamine acetate (2-HOBA) is taken daily for 12 weeks
PlaceboOther
Placebo taken three times per day for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety/Tolerability (adverse events)Time frame: Baseline to week 12
- Change in dicarbonyl protein adductsTime frame: Baseline to week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Cognitive Medicine, Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.